2023 World Conference on Lung Cancer (Posters)-EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2) - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the expression of miR-320b in extracellular vesicles as a prognostic factor for non-small cell lung carcinoma (NSCLC) after therapy. The study was conducted on 16 NSCLC patients at Dharmais Cancer Hospital and involved taking peripheral blood samples before and after therapy. The miR-320b levels were measured and compared among groups showing complete response, partial response, stable disease, and progressive disease. The results showed that after therapy, the miR-320b levels increased, although not significantly. The partial response group had a 28% decrease in miR-320b levels, while the stable disease group had a 21% decrease, and the progressive disease group had a 29% increase. However, there was no significant relationship between miR-320b levels and treatment response. In addition, there was no significant difference in miR-320b levels between patients undergoing chemotherapy and tyrosine kinase inhibitor therapy. <br /><br />The findings suggest that the decrease in miR-320b expression in the stable disease and partial response groups and the increase in the progressive disease group may occur as a mechanism of response in the tumor cell microenvironment to the therapeutic effects given to inhibit the progression of cancer cells. This indicates that miR-320b in extracellular vesicles could potentially serve as a prognostic biomarker for NSCLC. However, further research is needed to validate these findings and understand the role of miR-320b in NSCLC progression and treatment response.

Asset Subtitle

Wily Ariawan

Meta Tag

Speaker Wily Ariawan

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

miR-320b

extracellular vesicles

prognostic factor

non-small cell lung carcinoma

NSCLC

therapy

complete response

partial response

stable disease

progressive disease